Comparative Bioavailability of a Novel Fixed‐dose Combination Etoricoxib and Tramadol
Clinical Pharmacology in Drug Development · 2024
DOI: 10.1002/cpdd.1456 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2024. Verfasst von Lourdes Garza-Ocañas und 10 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacology and Toxicology Department, Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico. Hauptthemen laut MEDLINE: Etoricoxib, Tramadol, Cross-Over Studies, Biological Availability. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Multimodal analgesia is defined as using several drugs or techniques simultaneously to target different pain pathways or receptors to avoid pain propagation. This study evaluated the pharmacokinetic profile and comparative bioavailability of etoricoxib 90 mg and tramadol 50 mg dosing alone (reference drugs) or in a novel fixed‐dose combination (test drug) under fasting conditions in Mexican healthy volunteers. This was a randomized, open‐label, 3‐way, crossover, single‐dose, prospective, and longitudinal study with a 14‐day washout period. Eligible subjects were healthy Mexican adult volunteers. The drugs were dosing orally, according to the randomization sequence, after 10 hours of fasting and 4 hours before breakfast with 250 mL of water at room temperature. Serial blood samples were collected before and after dosing, both drugs were quantified using high‐performance liquid chromatography coupled with tandem mass spectrometry. Forty‐two subjects were enrolled and 38 completed the study (28 men and 14 women, mean age 25.2 years, mean weight 66.6 kg). Test products were considered to have comparative bioavailability if confidence intervals of natural log‐transformed for (maximum plasma drug concentration (C max ), (area under the plasma drug concentration‐time curve form 0 up to last sampling time (AUC 0‐t ), and (area under the plasma drug concentration‐time curve from 0 up to infinity (AUC 0‐∞ ) data were within the range of 80%‐125%. Non‐serious adverse events were observed. The results demonstrate that the pharmacokinetic profile and bioavailability of the etoricoxib/tramadol fixed‐dose combination are comparable to those of the reference products.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmacology and Toxicology Department, Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico.
- Research and Development Department, Laboratorios Silanes S.A. de C.V, Mexico City, 11000, Mexico.
- Instituto Mexicano del Seguro Social, Centro Médico Nacional Siglo XXI, Mexico City, Mexico.
Zitieren
APA
Garza-Ocañas, L., Badillo-Castaneda, C. T., Eguía, S. L. M., Zanatta-Calderón, M. T., Garza, J. D. T., Gómez-Meza, M. V., Sander-Padilla, J. G., Lugo-Sánchez, L. A., Rios-Brito, K. F., Romero-Antonio, Y., & González-Canudas, J. (2024). Comparative Bioavailability of a Novel Fixed‐dose Combination Etoricoxib and Tramadol. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1456
Vancouver
Garza-Ocañas L, Badillo-Castaneda CT, Eguía SLM, Zanatta-Calderón MT, Garza JDT, Gómez-Meza MV, et al. Comparative Bioavailability of a Novel Fixed‐dose Combination Etoricoxib and Tramadol. Clinical Pharmacology in Drug Development. 2024. doi:10.1002/cpdd.1456
BibTeX
@article{GarzaOcaas2024,
author = {Garza-Ocañas, Lourdes and Badillo-Castaneda, Christian T and Eguía, Sandra L Montoya and Zanatta-Calderón, María T and Garza, Julia D Torres and Gómez-Meza, Marco Vinicio and Sander-Padilla, José G and Lugo-Sánchez, Laura A and Rios-Brito, Kevin F and Romero-Antonio, Yulia and González-Canudas, Jorge},
title = {Comparative Bioavailability of a Novel Fixed‐dose Combination Etoricoxib and Tramadol},
journal = {Clinical Pharmacology in Drug Development},
year = {2024},
doi = {10.1002/cpdd.1456}
}
EUVIMED